A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 207-212

  Miller, Kathy D ^a   Loehrer, Patrick J ^a,g   Gonin, René ^a   Weber, George ^g   Ansari, Rafat ^b   Pletcher, William ^c   McClean, John ^d   Spiridonidis, C H ^e   Mortimer, Joanne ^f  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b Michiana Hematology/Oncology   (United States)

^c Elkart Clinic   (United States)

^d Galesburg Clinic   (United States)

^e Giant Medical Clinic   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Methotrexate; Pancreatic carcinoma; Thymidine synthesis; Zidovudine

Indexed keywords

HEMOGLOBIN; METHOTREXATE; ZIDOVUDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EDEMA; FATIGUE; FEMALE; FEVER; GRANULOCYTE; GRANULOCYTOPENIA; HUMAN; INFECTION COMPLICATION; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; PANCREATIC NEOPLASMS; REMISSION INDUCTION; ZIDOVUDINE;

EID: 0029800623     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00210792     Document Type: Article

References (23)

1. Cameron JL: The current management of carcinoma of the head of the pancreas. Ann Rev Med 16:361-370, 1995
2. Kaiser MH, Barkin J, MacIntrye JM: Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 56:397-402, 1985
3. O'Connell MJ: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3:1032-1039, 1985
4. Klaassen DJ, MacIntrye JM, Catton GE, Engstrom PF, Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-FU alone with radiation plus concurrent and maintenance 5-FU, an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373-378, 1985
5. Einhorn LH, Loehrer PJ: Ifosfamide chemotherapy for pancreatic carcinoma. Cancer Chemother Pharmacol 18(Suppl 2):S51-S54, 1986
6. Cornelison TL, Goldberg JM, Piver MS: Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma. J Surg Oncol 59:201-208, 1995
7. Nightingale S: From the Food and Drug Administration. JAMA 273:982, 1995
8. Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, Von Hoff D: A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer. (Abstract) Proc Am Soc Clin Oncol 14: 473, 1995
9. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa N, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56:918-928, 1985
10. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM: Hepatocellular carcinoma: a retrospective analysis of treatments to manage disease confined to the liver. Cancer 61:1884-1888, 1988
11. Lai ECS, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J: Doxorubicin for unresectable hepatocellular carcinoma: a prospective study on the addition of vera-pamil. Cancer 66:1685-1687, 1990
12. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ: Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 21: 1535-1542, 1995
13. Martinez Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, Vilardell F: Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 20:702-706, 1994
14. Melia WM, Johnson PJ, Williams R: Induction of remission in hepatocellular carcinoma: a comparison of VP-16 with adriamycin. Cancer 51:206-210, 1983
15. Kawata A, Una Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J, Kobayashi H: Adjuvant chemoimmuno-therapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 18:257-262, 1995
16. Toyoda H, Nakano S, Kumada T, Takeda I, Sigiyama K, Osada T, Kiriyama S, Suga T, Takahashi M: The efficacy of continuous local arterial infusion of 5-fluor-ouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295-299, 1995
17. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, Sakata Y: Clinical study of biological response modifiers as maintenance therapy for hepato-cellular carcinoma. Cancer Chemother Pharmacol 33 (Suppl):S145-S148, 1991
18. Yarchoan R, Mitsuya H, Myers CE, Broder S: Clinical pharmacology of 3′-azodo-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. NEJM 321: 726-738, 1989
19. Weber G, Ichikawa S, Nagai M, Natsumeda Y: Azido-thymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-FU in rat hepatoma and colon cancer cells. Cancer Commun 2:129-133, 1990
20. Weber G, Nagai M, Prajda N, Nakamura H, Szekeres T, Olah E: AZT: A biochemical response modifier of methotrexate and 5-FU cytotoxicity in human ovarian and pancreatic carcinoma cells. Cancer Commun 3:127-132, 1991
21. Zar JH: Biostatical Analysis, 2nd ed. Prentice-Hall, Englewood Cliffs, NJ, 1984, pp 138-146
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assoc 53:457-481, 1958
23. Winick N, Bowman PW, Arencibia-Mireles O, Kamen B: Prolonged intensive oral methotrexate does not induce its own malabsorption. Cancer Therapy and Control 1: 245-250, 1990